A variety of muscle protein biomarkers have been identified in plasma or serum in muscular dystrophy studies,17, 18 and recent studies have indicated an elevation of neurofilament light in CMT1A patients (NfL or NEFL).19 To identify the potential molecular biomarkers in plasma for CMT1A, we obtained and analyzed samples from 47 subjects with CMT1A and 41 controls without known neurological disease, and analyzed them using five Olink Immuno PCR assay panels to identify significant differences in expression of targeted proteins. This evidence concerns the gene NEFL and Charcot-Marie-Tooth disease type 1A.